CYTOF
Price
$0.08
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
Capitalization
457.24K
Intraday Buy/Sell Signals
VERU
Price
$4.11
Change
-$0.06 (-1.44%)
Updated
Oct 17, 11:28 AM (EDT)
Capitalization
61.09M
45 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

CYTOF vs VERU

Header iconCYTOF vs VERU Comparison
Open Charts CYTOF vs VERUBanner chart's image
Altamira Therapeutics
Price$0.08
Change-$0.00 (-0.00%)
Volume$309
Capitalization457.24K
Veru
Price$4.11
Change-$0.06 (-1.44%)
Volume$250
Capitalization61.09M
CYTOF vs VERU Comparison Chart in %
CYTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTOF vs. VERU commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTOF is a Hold and VERU is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (CYTOF: $0.08 vs. VERU: $4.17)
Brand notoriety: CYTOF and VERU are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTOF: 3% vs. VERU: 94%
Market capitalization -- CYTOF: $457.24K vs. VERU: $61.09M
CYTOF [@Biotechnology] is valued at $457.24K. VERU’s [@Biotechnology] market capitalization is $61.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTOF’s FA Score shows that 1 FA rating(s) are green whileVERU’s FA Score has 1 green FA rating(s).

  • CYTOF’s FA Score: 1 green, 4 red.
  • VERU’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTOF is a better buy in the long-term than VERU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTOF’s TA Score shows that 3 TA indicator(s) are bullish while VERU’s TA Score has 5 bullish TA indicator(s).

  • CYTOF’s TA Score: 3 bullish, 5 bearish.
  • VERU’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VERU is a better buy in the short-term than CYTOF.

Price Growth

CYTOF (@Biotechnology) experienced а -2.97% price change this week, while VERU (@Biotechnology) price change was -2.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.39%. For the same industry, the average monthly price growth was +17.05%, and the average quarterly price growth was +80.61%.

Reported Earning Dates

VERU is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VERU($61.1M) has a higher market cap than CYTOF($457K). VERU has higher P/E ratio than CYTOF: VERU (0.69) vs CYTOF (0.05). CYTOF YTD gains are higher at: -27.602 vs. VERU (-35.895). CYTOF has higher annual earnings (EBITDA): -5.46M vs. VERU (-36.5M). VERU has more cash in the bank: 15M vs. CYTOF (3.76K). CYTOF has less debt than VERU: CYTOF (790K) vs VERU (3.25M). VERU has higher revenues than CYTOF: VERU (16.9M) vs CYTOF (0).
CYTOFVERUCYTOF / VERU
Capitalization457K61.1M1%
EBITDA-5.46M-36.5M15%
Gain YTD-27.602-35.89577%
P/E Ratio0.050.698%
Revenue016.9M-
Total Cash3.76K15M0%
Total Debt790K3.25M24%
FUNDAMENTALS RATINGS
CYTOF vs VERU: Fundamental Ratings
CYTOF
VERU
OUTLOOK RATING
1..100
6817
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4663
P/E GROWTH RATING
1..100
10025
SEASONALITY SCORE
1..100
7590

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTOF's Valuation (7) in the Biotechnology industry is significantly better than the same rating for VERU (97) in the Household Or Personal Care industry. This means that CYTOF’s stock grew significantly faster than VERU’s over the last 12 months.

CYTOF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VERU (100) in the Household Or Personal Care industry. This means that CYTOF’s stock grew similarly to VERU’s over the last 12 months.

CYTOF's SMR Rating (100) in the Biotechnology industry is in the same range as VERU (100) in the Household Or Personal Care industry. This means that CYTOF’s stock grew similarly to VERU’s over the last 12 months.

CYTOF's Price Growth Rating (46) in the Biotechnology industry is in the same range as VERU (63) in the Household Or Personal Care industry. This means that CYTOF’s stock grew similarly to VERU’s over the last 12 months.

VERU's P/E Growth Rating (25) in the Household Or Personal Care industry is significantly better than the same rating for CYTOF (100) in the Biotechnology industry. This means that VERU’s stock grew significantly faster than CYTOF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTOFVERU
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
CYTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VERU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OXLCP24.550.01
+0.04%
Oxford Lane Capital Corp
VVX56.99-0.59
-1.02%
V2X
SARO27.90-0.43
-1.52%
StandardAero Inc
COFS26.29-1.51
-5.43%
ChoiceOne Financial Services
HOLO4.42-0.37
-7.72%
MicroCloud Hologram Inc

CYTOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTOF has been loosely correlated with CMND. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTOF jumps, then CMND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTOF
1D Price
Change %
CYTOF100%
N/A
CMND - CYTOF
56%
Loosely correlated
+0.10%
COGT - CYTOF
40%
Loosely correlated
-1.27%
SPHDF - CYTOF
35%
Loosely correlated
N/A
VTVT - CYTOF
29%
Poorly correlated
-7.23%
VERU - CYTOF
28%
Poorly correlated
-5.01%
More